Arizona Pulmonary Specialists, Ltd.

Phoenix, Arizona 85013

1 studies enrolling now · 24 studies all time

What they study most

Bronchiectasis, Chronic Obstructive Pulmonary Disease, Chronic Thromboembolic Pulmonary Hypertension, Combined Pulmonary Fibrosis and Emphysema, Complicated Urinary Tract Infection, Diastolic Heart Failure, Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Primary Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Embolism, Pulmonary Fibrosis

Studies at this site

• Pulmonary Hypertension Association Registry — Recruiting now
• Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis — Completed
• The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension — Completed
• Extension Study for Participants in LIQ861 Trials to Evaluate the Long-term Safety of Dry Powder Inhalation of Treprostinil — Running, not enrolling
• A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) — Stopped early
• Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil — Completed
• A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension — Stopped early
• Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH — Stopped early
• A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure — Completed
• An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE — Stopped early
• Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE — Completed
• An Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial Hypertension — Completed
• An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension — Completed
• To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension. — Stopped early
• Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy — Completed
• Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill — Completed
• Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections — Completed
• Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) — Stopped early
• Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies — Completed
• Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness — Completed
• Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis — Completed
• Safety and Efficacy Study of Ambrisentan in Subjects With Pulmonary Hypertension — Completed
• Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease — Completed
• Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension — Withdrawn before enrolling